TrialBMC infectious diseases2022

Indirect comparison of 48-week efficacy and safety of long-acting cabotegravir and rilpivirine maintenance every 8 weeks with daily oral standard of care antiretroviral therapy in participants with virologically suppressed HIV-1-infection.

Vasiliki Chounta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.